← Russell 3000 cross-section

CYTK CYTOKINETICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$11.0bn
Revenue TTM
$68m
Net income TTM
$-894m
Free cash flow
$-581m
Composite score
27.8
Sector rank
#673

Valuation

P / E
EV / EBITDA
EV / sales
148.5
FCF yield
-5.30%
Earnings yield vs 10-yr
-12.88pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-1,321.1%
EBITDA margin
-1,027.6%
ROE
515.3%
ROIC
Revenue growth
-21.1%

Insider activity, last 90 days

Net open-market
$-11.99m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations Revenues Our revenues since inception were primarily from our collaboration partners. Revenues for the three and six months ended June 30, 2026 and 2025, were as follows (in thousands): Net product revenue was recorded for our commercial sales of MYQORZO commencing in the last week of January 2026, for the three and six months ended June 30, 2026. Net product revenue by geographic area for the three and six months ended June 30, 2026 and 2025, were as follows (in thousands): Collaboration revenues for the three and six months ended June 30, 2026 and 2025 were primarily from Bayer under the Bayer License Agreement related to certain research and development cost reimburs …CYTOKINETICS INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →